Association between HDL-C concentration and risk for a major cardiovascular event

Current Medical Research and Opinion

Volumn 26, Issue 4, 2010, Pages 933-941

  Laitinen, David L ^a   Manthena, Shivaji ^a   Webb, Silky ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Cardiovascular diseases; Cholesterol; Coronary heart diseases; Dyslipidemia; HDL

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; UNITED STATES;

EID: 77949500644     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003656968     Document Type: Article

References (35)

1. Cobain MR, Pencina MJ, D'Agostinoo Sr RB, et al. Lifetime risk for developing dyslipidemia: the Framingham Offspring Study. Am J Med 2007;120:623-630
2. Zhang B, Menzin J, Friedman M, et al. Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey. Curr Med Res Opin 2008;24:2711-2717
3. Bermúdez V, Cano R, Cano C, et al. Pharmacologic management of isolated low high-density lipoprotein syndrome. Am J Ther 2008;15:377-388
4. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a predictive factor against coronary heart disease: the Framingham study. Am J Med 1977;62:707-714
5. Alagona P. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care 2009;15:S65-73
6. Ghazzal ZB, Dhawan SS, Sheikh A, et al. Usefulness of serum high-density lipoprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions. Am J Cardiol 2009;103:902-906
7. DeGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 2008;51:49-55
8. Ballantyne CM. A new look at mixed dyslipidemia. Medscape CME. Available at: http://www.medscape.com/viewarticle/570903 [Last accessed 12 November 2009]
9. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J 2008; 84:590-598
10. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310
11. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179-1184
12. Wilson PW, Garrison RJ, Castelli WP, et al. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 1980;46:649-654
13. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15
14. Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, et al. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med 2003;163:1549-1554
15. Cardenas GA, Lavie CJ, Cardenas V, et al. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med 2008;9: 239-258
16. LaMarche B, Després JP, Moorjani S, et al. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Qué bec cardiovascular study. Atherosclerosis 1996;119:235-245
17. Cannon CP, Braunwald E, McCabe CH, et al. Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
18. Shepherd J, Kastelein JJ, Bittner V, et al. Treating to New Targets Investigators. Effective of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treatment to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1100-1103
19. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003;18:1039-1052
20. Coleman RL, Stevens RJ. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diab Care 2007;30:1292-1294
21. D'Agostino RB, Grundy SM, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-187
22. Ramachandran S, French JM, Vanderpump MPJ, et al. Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. BMJ 2000;320:676-677
23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-3421
24. Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-2372
25. Grundy SM, D'Agostino Sr RB, Mosca L, et al. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop. Circulation 2001;104:491-496
26. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006; 17:631-636
27. Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. Available at: http://www.cms.hhs.gov/ HIPAAGenInfo/Downloads/HIPAALaw.pdf [Last accessed 12 November 2009]
28. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92
29. Tardif JC, Gregoire J, L'Alliere PL, et al. Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675-1682
30. Dean BB, Borenstein JE, Henning JM, et al. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Am Heart J 2004; 147:966-976
31. Cannon CP. High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. Clin Cornerstone 2007;8:S14-23
32. Keys A. Alpha lipoprotein (HDL) cholesterol in the serum and the risk of coronary heart disease and death. Lancet 1980;2:603-606
33. Toth PP, Zarotsky V, Sullivan JM, et al. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. Curr Med Res Opin 2009;8:26
34. Tenenbaum A, Fisman E, Motro M, et al. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006;5:20
35. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetemibe and carotid intima-media thickness. N Engl J Med 2009;361: 2113-2122